ERBB2 and breast cancer: In our study, downregulation of both miR-100 and miR-452 suppressed trastuzumab resistance, multiple chemoresistance, and CSC-like properties, thus supporting their oncogenic roles in HER2-positive breast cancer as targets of LINC00589.